Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

Endocrinology

Volumn 148, Issue 6, 2007, Pages 2669-2680

  Lazarenko, Oxana P ^a   Rzonca, Sylwia O ^a,c   Hogue, William R ^b   Swain, Frances L ^b   Suva, Larry J ^b   Lecka Czernik, Beata ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE AGE; BONE GROWTH; BONE MARROW CELL; BONE MASS; BONE STRENGTH; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGING; ANIMALS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CELL DIFFERENTIATION; COMPRESSIVE STRENGTH; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34250847265     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-1587     Document Type: Article

References (46)

1. U.S. Department of Health and Human Services 2004 Bone Health and Osteoporosis: a report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
2. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
3. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855
4. Lehrke M, Lazar MA 2005 The many faces of PPARγ. Cell 123:993-999
5. Rosen CJ, Bouxsein ML 2006 Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35-43
6. Manolagas SC 1998 Cellular and molecular mechanisms of osteoporosis. Aging 10:182-190
7. Moore SG, Dawson KL 1990 Red and yellow marrow in the femur: age-related changes in appearance at MR imaging. Radiology 175:219-223
8. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM 2002 Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49
9. Aubin JE 2001 Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2:81-94
10. Lecka-Czernik B, Gubrij I, Moerman EA, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-γ2. J Cell Biochem 74:357-371
11. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B 2004 Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell 3:379-389
12. Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP 2005 Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 20:1659-1668
13. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 16:27-32
14. Willson TM, Lambert MH, Kliewer SA 2001 Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 70:341-367
15. Sottile V, Seuwen K, Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337
16. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216
17. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, Auwerx J 2004 Enhanced bone formation in lipodystrophic PPARγ(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 5:1007-1012
18. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235
19. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Won Park S, Lane NE, Harris TB, Cummings SR 2006 Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
20. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S 1999 Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor γ gene: PPARγ expression in osteoblasts. Biochem Biophys Res Commun 260:122-126
21. Kiel DP, Ferrari S, Cupples LA, Karasik D, Dupuis J, Rosen CJ, Imamovic A, Demissie S 2005 Polymorphism in the PPARγ influence bone density in humans. J Bone Miner Res 20:S234
22. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B 2006 Netoglitazone is a PPAR-γ ligand with selective effects on bone and fat. Bone 38:74-85
23. Aronson J, Hogue WR, Flahiff CM, Gao GG, Shen XC, Skinner RA, Badger TM, Lumpkin CK, Jr 2001 Development of tensile strength during distraction osteogenesis in a rat model. J Orthop Res 19:64-69
24. Suva LJ, Seedor JG, Endo N, Quartuccio HA, Thompson DD, Bab I, Rodan GA1993 Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res 8:379-388
25. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
26. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
27. Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S 2002 Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 17:1044-1050
28. Parfitt AM 1984 Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences. Calcif Tissue Int 36:S123-S128
29. Werner AL, Travaglini MT 2001 A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21:1082-1099
30. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D 2004 The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475
31. Teitelbaum SL, Ross FP 2003 Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
32. Asagiri M, Takayanagi H 2007 The molecular understanding of osteoclast differentiation. Bone 40:251-264
33. Teitelbaum SL, Tondravi MM, Ross FP 1997 Osteoclasts, macrophages, and the molecular mechanisms of bone resorption. J Leukoc Biol 61:381-388
34. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW 2001 IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1. Proc Natl Acad Sci USA 98:2443-2448
35. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y 1999 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065
36. Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA 2007 PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40:149-159
37. Muraglia A, Cancedda R, Quarto R 2000 Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 113:1161-1166
38. Fehrer C, Lepperdinger G 2005 Mesenchymal stem cell aging. Exp Gerontol 40:926-930
39. Watts NB, D'Alessio DA 2006 Type 2 diabetes, thiazolidinediones: bad to the bone? J Clin Endocrinol Metab 91:3276-3278
40. Silverstein JH, Rosenbloom AL 2001 Type 2 diabetes in children. Curr Diab Rep 1:19-27
41. Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH 2005 Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology 146:4349-4361
42. Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW 2006 Activation of receptor activator of NF-κB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol 26:6469-6486
43. Fu Q, Manolagas SC, O'Brien CA 2006 Parathyroid hormone controls receptor activator of NF-κB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol 26:6453-6468
44. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R, Gantner BN, Dinner AR, Singh H 2006 Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 126:755-766
45. Lecka-Czernik B, Teng K, Lazarenko OP 2004 Glitazones, the anti-diabetic PPAR-γ agonists, suppress osteoblast differentiation and the activity of TGF-β/BMP signaling pathways. J Bone Miner Res 19:SA171
46. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ 2007 Activation of peroxisome proliferator-activated receptor γ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148:903-911